FDA published a webcast of a public hearing on the agency’s approach to enhancing competition and innovation in the biological products marketplace, including by facilitating greater availability of biosimilar and interchangeable products. The agenda included comments from commissioner Gottlieb and about twenty speakers who were allotted about ten minutes, which included questions by the panel.
[membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
